Silvana Canevari
Overview
Explore the profile of Silvana Canevari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
120
Citations
3245
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cavalieri S, Serafini M, Carenzo A, Canevari S, Brakenhoff R, Leemans C, et al.
JCO Precis Oncol
. 2021 Nov;
5.
PMID: 34738049
Methods: Patients with HPV DNA-positive OPCs with locoregionally advanced nonmetastatic disease treated with curative intent (BD2Decide observational study, NCT02832102) were considered as validation cohort. Patients were treated in seven European...
12.
Cavalieri S, De Cecco L, Brakenhoff R, Serafini M, Canevari S, Rossi S, et al.
Head Neck
. 2020 Oct;
43(2):601-612.
PMID: 33107152
Background: Despite advances in treatments, 30% to 50% of stage III-IV head and neck squamous cell carcinoma (HNSCC) patients relapse within 2 years after treatment. The Big Data to Decide...
13.
Califano D, Russo D, Scognamiglio G, Losito N, Spina A, Bello A, et al.
Cells
. 2020 Apr;
9(4).
PMID: 32272732
Ovarian cancer is the most lethal gynecological cancer, and despite years of research, with the exception of a BRCA mutation driving the use of PARP inhibitors, no new prognostic/predictive biomarkers...
14.
Locati L, Serafini M, Ianno M, Carenzo A, Orlandi E, Resteghin C, et al.
Cancers (Basel)
. 2019 Jul;
11(8).
PMID: 31357501
Patients (pts) with head and neck squamous cell carcinoma (HNSCC) have different epidemiologic, clinical, and outcome behaviors in relation to human papillomavirus (HPV) infection status, with HPV-positive patients having a...
15.
De Cecco L, Serafini M, Facco C, Granata R, Orlandi E, Fallai C, et al.
Oral Oncol
. 2019 Mar;
90:94-101.
PMID: 30846184
Epithelial sinonasal cancers (SNCs) are rare diseases with overlapping morphological features and a dismal prognosis. We aimed to investigate the expression differences among the histological subtypes for discerning their molecular...
16.
Devecchi A, De Cecco L, Dugo M, Penso D, Dagrada G, Brich S, et al.
Cancer Commun (Lond)
. 2018 Nov;
38(1):70.
PMID: 30486883
Background: Desmoplastic small round cell tumor (DSRCT) is a rare, aggressive, and poorly investigated simple sarcoma with a low frequency of genetic deregulation other than an Ewing sarcoma RNA binding...
17.
Canese R, Palombelli G, Chirico M, Sestili P, Bagnoli M, Canevari S, et al.
NMR Biomed
. 2018 Oct;
32(10):e4016.
PMID: 30375088
Although several drugs are available to treat recurrences of human epithelial ovarian cancer (EOC), clinical responses often remain short lived and lead to only marginal improvements in patients' survival. One...
18.
Cheung A, Opzoomer J, Ilieva K, Gazinska P, Hoffmann R, Mirza H, et al.
Clin Cancer Res
. 2018 Aug;
24(20):5098-5111.
PMID: 30068707
Highly aggressive triple-negative breast cancers (TNBCs) lack validated therapeutic targets and have high risk of metastatic disease. Folate receptor alpha (FRα) is a central mediator of cell growth regulation that...
19.
Rea K, Roggiani F, De Cecco L, Raspagliesi F, Carcangiu M, Nair-Menon J, et al.
J Exp Clin Cancer Res
. 2018 Jul;
37(1):146.
PMID: 29996940
Background: The disruption of E-cadherin-mediated adhesion is considered an important driver of tumor progression. Nevertheless, numerous studies have demonstrated that E-cadherin promotes growth- or invasion-related signaling, contrary to the prevailing...
20.
Satta A, Mezzanzanica D, Caroli F, Frigerio B, Di Nicola M, Kontermann R, et al.
MAbs
. 2018 Jul;
10(7):1084-1097.
PMID: 29993310
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or TRAIL-receptor agonistic monoclonal antibodies promote apoptosis in most cancer cells, and the differential expression of TRAIL-R2 between tumor and normal tissues...